In a report released yesterday, Liana Moussatos from Wedbush reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), with a price target of $80. The company’s shares opened today at $37.05.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.4% and a 45.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $46.44.
See today’s analyst top recommended stocks >>
The company has a one-year high of $51.10 and a one-year low of $26.95. Currently, Pacira Pharmaceuticals has an average volume of 937.6K.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
